Esperion(ESPR) - 2025 Q3 - Quarterly Results

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update – Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Prior to April 2040 – ® ® – Bempedoic Acid Received Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dysl ...